Canaccord lowered the firm’s price target on Exagen (XGN) to $8 from $10 and keeps a Buy rating on the shares. The firm updated its model ahead of Q results and noted the company’s decline in sequential quarterly ASP over the last three quarters has been partially driven by headwinds including the loss of a high ASP payer. They remain confident that Exagen’s management can execute on its strategy over time.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XGN:
- Exagen price target lowered to $10 from $12 at Craig-Hallum
- Exagen price target lowered to $10 from $15 at Canaccord
- Exagen price target lowered to $10 from $15 at KeyBanc
- Exagen price target lowered to $9 from $10 at BTIG
- Maintaining a Buy: Conservative Guidance but Solid Demand and Pipeline Support Long-Term Upside